|
|
Reference
|
|
   2
|
Antman, E.M., Louwerenburg, H.W., Baars, H.F., Wesdorp, J.C.L., Hamer, B., Bassand, J., Bigonzi, F., Pisapia, G., Gibson, C.M., Heidbuchel, H., Braunwald, E., van de Werf, F. (2002) Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation, 105(14): 1642-9
|
|
6
|
Antman, E.M., Morrow, D.A., McCabe, C.H., Murphy, S.A., Ruda, M., i dr. (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. New England Journal of Medicine, 354(14), 1477-1488
|
|
9
|
Antman, E.M., McCabe, C.H., Gurfinkel, E.P., Turpie, A.G., Bernink, P.J., Salein, D., de Bayes, L.A., Fox, K., Lablanche, J.M., Radley, D., Premmereur, J., Braunwald, E. (1999) Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation, 100(15): 1593-601
|
|
11
|
Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators (2001) Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet, 358(9282): 605-13
|
|
|
Blazing, M.A., Lemos, J.A., White, H.D., Fox, K.A.A., Verheugt, F.W.A., i dr. (2004) Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. JAMA, 292(1): 55-64
|
|
4
|
Cohen, M., Demers, C., Gurfinkel, E.P., Turpie, A.G., Fromell, G.J., Goodman, S., Langer, A., Califf, R.M., Fox, K.A., Premmereur, J., Bigonzi, F. (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med, 337(7): 447-52
|
|
2
|
Cohen, M., Gensini, G.F., Maritz, F., Gurfinkel, E.P., Huber, K., Timerman, A., Krzeminska-Pakula, M., Danchin, N., White, H.D., Santopinto, J., Bigonzi, F., Hecquet, C., Vittori, L., TETAMI Investigators (2003) The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): A randomized. J Am Coll Cardiol, 42(8): 1348-56
|
|
|
Cohen, M., Theroux, P., Borzak, S., Frey, M.J., White, H.D., van Mieghem, W., Senatore, F., Lis, J., Mukherjee, R., Harris, K., Bigonzi, F., ACUTE II Investigators (2002) Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study. The Antithrombotic Combination Using Tirofiban. Am Heart J, 144(3): 470-7
|
|
4
|
Ferguson, J.J., Califf, R.M., Antman, E.M., Cohen, M., Grines, C.L., Goodman, S., Kereiakes, D.J., Langer, A., Mahaffey, K.W., Nessel, C.C. (2004) Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA, 292(1): 45-54
|
|
|
Goodman, S.G., Fitchett, D., Armstrong, P.W., Tan, M., Langer, A., Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators (2003) Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation, 107(2): 238-44
|
|
|
Montalescot, G., Bal--Sollier, C., Chibedi, D., Collet, J., Soulat, T., Dalby, M., Choussat, R., Cohen, A., Slama, M., Steg, P., i dr. (2003) Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). Am J Cardiol, 91(8): 925-30
|
|
|
Montalescot, G., White, H.D., Gallo, R., Cohen, M., Steg, G.P., Aylward, P.E.G., Bode, C., Chiariello, M., King, S.B.I.I.I., Harrington, R.A., Desmet, W.J., Macaya, C., Steinhubl, S.R. (2006) Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. New England Journal of Medicine, 355(10), 1006-1017
|
|
5
|
Ross, A.M., Molhoek, P., Lundergan, C., Knudtson, M., Draoui, Y., Regalado, L., le Louer, V., Bigonzi, F., Schwartz, W., de Jong, E., Coyne, K., HART II Investigators (2001) Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation, 104(6): 648-52
|
|
2
|
Sabatine, M.S., Morrow, D.A., Montalescot, G., Dellborg, M., Leiva-Pons, J.L., Keltai, M., Murphy, S.A., McCabe, C.H., Gibson, M.C., Cannon, C.P., Antman, E.M., Braunwald, E. (2005) Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in st-elevation myocardial infarction treated with fibrinolytics in the clarity-timi 28 trial. Circulation, 112(25), 3846-3854
|
|
6
|
Simoons, M., Krzemiñska-Pakula, M., Alonso, A., Goodman, S., Kali, A., Loos, U., Gosset, F., Louer, V., Bigonzi, F., AMI-SK Investigator (2002) Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J, 23(16): 1282-90
|
|
|
Wallentin, L., Goldstein, P., Armstrong, P.W., Granger, C.B., Adgey, A.A.J., Arntz, H.R., Bogaerts, K., Danays, T., Lindahl, B., Makijarvi, M., Verheugt, F., van Werf, F. (2003) Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomiz. Circulation, 108(2): 135-42
|
|
|
|
|